Analysis: Thank you to Novartis for not increasing your prices on pres...

8y ago Jul 19, 2018 at 10:23 AM

Thank you to Novartis for not increasing your prices on prescription drugs. Likewise to Pfizer. We are making a big push to actually reduce the prices, maybe substantially, on prescription drugs.

0:00 0:00

AI Analysis

Machine-generated analysis of the post above on 2026-03-15. Not written by the author of the post.

Danger Level

None

Narcissistic State

Grandiose

Authorship

Uncertain

Intensity

18%

Authorship Analysis

Uncertain

Indicators:

6:23 AM EDT local time — within authentic early-morning window
Hedging phrase 'maybe substantially' is characteristic Trump qualifier
Gratitude framing ('Thank you to X for not doing Y') appears in other authentic posts
Content is unusually policy-coherent and restrained for unmediated Trump
Correct grammar and punctuation favor aide involvement

Psychological Profile

▶ State

Grandiose State

Trigger: Maintenance (Helsinki summit fallout and bipartisan outrage dominating the news cycle)

Sentiment

+0.55

▶ Clinical

Malignant Narcissism:

Narcissistic

20%

Antisocial

Paranoid

Sadism

Defense Mechanisms:

displacementrationalization

Cognitive Complexity:

Complexity

32%

Parasocial Techniques:

Gratitude-to-corporations as surrogate consumer advocacy — positions subject as champion of ordinary Americans against pharmaceutical industry

Fact Checks (3)

"Novartis has not increased prescription drug prices"

Mostly True

Novartis had committed to a price freeze in 2018 consistent with White House pressure on the pharmaceutical sector.

"Pfizer has not increased prescription drug prices"

Half True

Pfizer initially announced price increases in July 2018, then reversed them after Trump's public criticism — so at the moment of this post, Pfizer had walked back increases but the reversal was recent and directly preceded by Trump tweets, not the 'no increase' framing here.

"We are making a big push to reduce prices, maybe substantially"

Half True

The administration did release a drug pricing blueprint (May 2018) and applied public pressure on pharma companies, but no substantial legislated price reductions materialized in this period. Rhetorical pressure achieved some voluntary freezes, not structural reduction.

Receipts

No contradictions with other posts detected yet.

Analysis: July 19, 2018 — Pharmaceutical Pricing Post

Contextual Frame

This post arrives at the precise nadir of the Helsinki crisis: bipartisan condemnation of Trump's press conference deference to Putin is at peak intensity, the Maria Butina arrest has just occurred, and the administration is in damage-control mode (Trump's implausible "wouldn't/would" retraction). Against this backdrop, a calm, consumer-friendly domestic policy tweet is not coincidental — it is strategic displacement.

Authorship

Timing (6:23 AM EDT) falls within Trump's documented early-morning posting window, lending some authenticity. The hedging phrase "maybe substantially" is a characteristic Trump qualifier appearing across verified authentic posts, and the backhanded-gratitude structure ("thank you for not doing X") matches his rhetorical fingerprint. However, the grammatical correctness, absence of ALL CAPS, and coherent policy logic suggest aide involvement. Assessment: collaborative origin — aide-framed with authentic Trumpian voice elements retained.

Psychological Dynamics

Level 1 (Traits): Unusually low neuroticism signal for the period. Agreeableness elevated relative to baseline. Conscientiousness facet (achievement-striving) present in policy-claim mode.

Level 2 (Motives): Agency motive dominant — credit-claiming via gratitude. Weak communion signal (consumer advocacy as proxy care).

Level 3 (Narrative): Subject as dealmaker-protector: industry yields to his pressure, Americans benefit. Protagonist cast as effective power-broker even in a cooperative register.

Defense Mechanisms: Displacement is the primary mechanism — pivot from existential reputational threat to safe populist terrain. Rationalization secondary ("we are making a big push" asserts causal agency without evidence).

Fact Verification

Claim	Verdict	Evidence
"Novartis has not increased prescription drug prices"	Mostly True	Novartis had committed to a price freeze in 2018 consistent with White House pressure on the pharmaceutical sector.
"Pfizer has not increased prescription drug prices"	Half True	Pfizer initially announced price increases in July 2018, then reversed them after Trump's public criticism — so at the moment of this post, Pfizer had walked back increases but the reversal was recent and directly preceded by Trump tweets, not the 'no increase' framing here.
"We are making a big push to reduce prices, maybe substantially"	Half True	The administration did release a drug pricing blueprint (May 2018) and applied public pressure on pharma companies, but no substantial legislated price reductions materialized in this period. Rhetorical pressure achieved some voluntary freezes, not structural reduction.

Overall Veracity: 60%

Danger Assessment

None. This is a benign policy communication with no threat language, dehumanization, or mobilization signals.

Longitudinal Note

The tonal departure from surrounding posts (ICE/MS-13 conflation, Turkey hostage anger, Russia meddling defensiveness) is stark. This controlled, positive register under acute political pressure is consistent with managed communication rather than authentic emotional discharge — a pattern worth tracking as an indicator of institutional crisis response mode.